

advancing cancer care through professional education

Fifth Annual New York Lung Cancer Symposium

The Westin New York at Times Square
New York, NY
November 10, 2009

Agenda Last Updated: September 8, 2010 (be sure to check that this agenda is the latest version)

Tuesday, Nov 10, 2009

7:30 am	Registration and Continental Breakfast	
8:00 am	Welcome and Introductions	<i>Vincent Miller, Román Pérez-Soler</i>
8:05 am	Presession Survey	
What Oncologists Need to Know About Lung Cancer Pathology		
8:15 am	New Technologies to Diagnose Lung Cancer Subtypes	
8:35 am	Algorithmic Approaches for Small Biopsy Specimens: Getting More Information From Less Tissue	<i>William D. Travis</i>
8:55 am	Molecular Subtyping of Lung Cancer	<i>Marc Ladanyi</i>
9:15 am	Panel Discussion/Question-and-Answer Session	
Maintenance Therapy in Advanced NSCLC		
9:30 am	Chemotherapy	<i>Nasser H. Hanna</i>
9:50 am	Targeted Agents	<i>Vincent Miller</i>
	Debate: Maintenance Therapy Should Be the Standard of Care	
10:10 am	PRO	<i>Richard Gralla</i>
10:25 am	CON	<i>Heather Wakelee</i>
10:40 am	Panel Discussion/Question-and-Answer Session	
10:35 am	Break	
Approaches to Early NSCLC and Chemoprevention		
10:50 am	Current Approaches to Adjuvant Therapy in Resectable NSCLC	<i>Steven M. Keller</i>
11:10 am	Nonsurgical Interventions for Early Lung Cancer	<i>Stephen Solomon</i>
11:30 am	Chemoprevention in Lung Cancer	<i>Fadlo R. Khuri</i>
11:50 am	Postsession Survey	
12:00 pm	Panel Discussion/Question-and-Answer Session	
12:15 pm	Break to Serve Lunch	

12:25 pm	Fellows Case Discussion Session and Working Lunch	<i>Abraham Chachoua, Harry Raftopoulos</i>
1:25 pm	Presession Survey	
Novel Agents and Applications for Lung Cancer		
1:35 pm	Overview	<i>Alex Adjei</i>
1:55 pm	Angiogenesis Inhibitors: What's New?	<i>Román Pérez-Soler</i>
2:10 pm	EML4-ALK-Positive Lung Cancer: Therapeutic Approaches for an Emerging Subtype	<i>Lecia V. Sequist</i>
2:25 pm	Update on the Role of IGF-1R Inhibitors	<i>Mark G. Kris</i>
2:40 pm	What's New With EGFR Inhibitors: Biomarkers and Frontline TKI Use	
3:10 pm	Update on Adverse Events With Novel Agents/Chemotherapy	<i>Román Pérez-Soler</i>
3:30 pm	Postsession Survey	
3:40 pm	Panel Discussion/Question-and-Answer Session	
4:00 pm	Adjourn	